Enlivex Therapeutics Ltd (ENLV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.80 (+9.69%), Market cap $0.17B, P/E ratio 0.03, 52-week low–high $0.67 ~ $1.82.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in
Financial statements, price targets, institutional (13F) holdings and related news for Enlivex Therapeutics Ltd are updated in real time on BlackAll Trade.
Enlivex Therapeutics Ltd trades at $0.80 (+9.69%). Real-time quotes and charts are available on BlackAll Trade.
Enlivex Therapeutics Ltd has a market cap of about $0.17B. Its P/E ratio is 0.03.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophag